VTRS: Viatris Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 13,775.80
Enterprise Value ($M) 30,915.50
Book Value ($M) 20,467.40
Book Value / Share 17.23
Price / Book 0.67
NCAV ($M) -14,242.00
NCAV / Share -11.99
Price / NCAV -0.97

Profitability (mra)
Return on Invested Capital (ROIC) 0.00
Return on Assets (ROA) 0.00
Return on Equity (ROE) 0.00

Liquidity (mrq)
Quick Ratio 1.22
Current Ratio 1.67

Balance Sheet (mrq) ($M)
Current Assets 12,976.10
Assets 47,685.50
Liabilities 27,218.10
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 15,426.90
Operating Income 1,999.40
Net Income 54.70
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 2,799.60
Cash from Investing -764.10
Cash from Financing -2,301.90

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-13 13G/A Vanguard Group Inc 11.86 -4.73
02-09 13G Davis Selected Advisers 5.20
01-30 13G/A State Street Corp 5.17 0.11
01-26 13G/A BlackRock Inc. 7.70 -0.94

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2023-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2023-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2023-04-28 10-K/A UN I TED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ Transition

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-03-27 1,349,504 7,808,288 17.28
2024-03-26 1,047,420 6,625,199 15.81
2024-03-25 590,740 3,533,568 16.72
2024-03-22 668,964 4,332,218 15.44

(click for more detail)

Similar Companies
VIRX – Viracta Therapeutics, Inc. VOR – Vor Biopharma Inc.
VRTX – Vertex Pharmaceuticals Incorporated VTYX – Ventyx Biosciences, Inc.
VYGR – Voyager Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io